Literature DB >> 27538675

Sweet taste pleasantness is modulated by morphine and naltrexone.

Marie Eikemo1,2,3, Guro E Løseth4, Tom Johnstone5, Johannes Gjerstad6,7, Frode Willoch7, Siri Leknes4,8.   

Abstract

BACKGROUND: Rodent models highlight the key role of μ-opioid receptor (MOR) signaling in palatable food consumption. In humans, however, the effects of MOR stimulation on eating and food liking remain unclear.
OBJECTIVES: Here, we tested sweet pleasantness experience in humans following MOR drug manipulations. We hypothesized that behaviors regulated by the endogenous MOR system would be enhanced by MOR agonism and decreased by antagonism. In line with rodent findings, we expected the strongest drug effects for the sweetest (high-calorie) sucrose stimuli. As very sweet stimuli are considered aversive by many people (called sweet dislikers), we also assessed whether MOR manipulations affect pleasantness ratings of sucrose-water stimuli differently depending on subjective and objective value.
METHODS: In a bidirectional psychopharmacological cross-over study, 49 healthy men underwent a sweet taste paradigm following double-blind administration of the MOR agonist morphine, placebo, and the opioid antagonist naltrexone.
RESULTS: As hypothesized, MOR stimulation with morphine increased pleasantness of the sweetest of five sucrose solutions, without enhancing pleasantness of the lower-sucrose solutions. For opioid antagonism, an opposite pattern was observed for the sweetest drink only. The observed drug effects on pleasantness of the sweetest drink did not differ between sweet likers and dislikers.
CONCLUSIONS: The bidirectional effect of agonist and antagonist treatment aligns with rodent findings showing that MOR manipulations most strongly affect the highest-calorie foods. We speculate that the MOR system promotes survival in part by increasing concordance between the objective (caloric) and subjective (hedonic) value of food stimuli, so that feeding behavior becomes more focused on the richest food available.

Entities:  

Keywords:  Food; Human; Morphine; Naltrexone; Opioid system

Mesh:

Substances:

Year:  2016        PMID: 27538675     DOI: 10.1007/s00213-016-4403-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  65 in total

1.  What and when to "want"? Amygdala-based focusing of incentive salience upon sugar and sex.

Authors:  Stephen V Mahler; Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2011-12-14       Impact factor: 4.530

Review 2.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.

Authors:  Ralitza Gueorguieva; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2004-03

3.  Perceived intensity and pleasantness of sucrose taste in male alcoholics.

Authors:  Michal Wronski; Dominika Skrok-Wolska; Jerzy Samochowiec; Marcin Ziolkowski; Lukasz Swiecicki; Przemyslaw Bienkowski; Agnieszka Korkosz; Paweł Zatorski; Wojciech Kukwa; Anna Scinska
Journal:  Alcohol Alcohol       Date:  2007-01-31       Impact factor: 2.826

4.  How does pain affect eating and food pleasure?

Authors:  S Leknes; B Bastian
Journal:  Pain       Date:  2014-01-10       Impact factor: 6.961

5.  Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Authors:  Marta Peciña; Tiffany Love; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-10-13       Impact factor: 7.853

6.  A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.

Authors:  R P Snaith; M Hamilton; S Morley; A Humayan; D Hargreaves; P Trigwell
Journal:  Br J Psychiatry       Date:  1995-07       Impact factor: 9.319

7.  Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors.

Authors:  R L McLeod; L E Parra; J C Mutter; C H Erickson; G J Carey; D B Tulshian; A B Fawzi; A Smith-Torhan; R W Egan; F M Cuss; J A Hey
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

8.  A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

Review 9.  Clinical pharmacokinetics of morphine.

Authors:  Ralph A Lugo; Steven E Kern
Journal:  J Pain Palliat Care Pharmacother       Date:  2002

10.  Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans.

Authors:  M Bertino; G K Beauchamp; K Engelman
Journal:  Am J Physiol       Date:  1991-07
View more
  22 in total

1.  Intact responses to non-drug rewards in long-term opioid maintenance treatment.

Authors:  Marie Eikemo; Philipp P Lobmaier; Mads L Pedersen; Nikolaj Kunøe; Anna Maria Matziorinis; Siri Leknes; Monica Sarfi
Journal:  Neuropsychopharmacology       Date:  2019-03-31       Impact factor: 7.853

2.  Associations between opioid dependence and sweet taste preference.

Authors:  Joshua B B Garfield; Dan I Lubman
Journal:  Psychopharmacology (Berl)       Date:  2021-02-01       Impact factor: 4.530

3.  Opioid Modulation of Value-Based Decision-Making in Healthy Humans.

Authors:  Marie Eikemo; Guido Biele; Frode Willoch; Lotte Thomsen; Siri Leknes
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

4.  Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade.

Authors:  Martin Trøstheim; Marie Eikemo; Jan Haaker; J James Frost; Siri Leknes
Journal:  Neuropsychopharmacology       Date:  2022-08-17       Impact factor: 8.294

5.  Dopaminergic and opioidergic regulation during anticipation and consumption of social and nonsocial rewards.

Authors:  Sebastian Korb; Sebastian J Götzendorfer; Claudia Massaccesi; Patrick Sezen; Irene Graf; Matthäus Willeit; Christoph Eisenegger; Giorgia Silani
Journal:  Elife       Date:  2020-10-13       Impact factor: 8.140

6.  Opioid-Independent and Opioid-Mediated Modes of Pain Modulation.

Authors:  Chantal Berna; Siri Leknes; Asma H Ahmad; Roisin N Mhuircheartaigh; Guy M Goodwin; Irene Tracey
Journal:  J Neurosci       Date:  2018-09-10       Impact factor: 6.167

7.  Dissociable control of μ-opioid-driven hyperphagia vs. food impulsivity across subregions of medial prefrontal, orbitofrontal, and insular cortex.

Authors:  Juliana L Giacomini; Emma Geiduschek; Ryan A Selleck; Ken Sadeghian; Brian A Baldo
Journal:  Neuropsychopharmacology       Date:  2021-07-05       Impact factor: 8.294

8.  Economic choice between remifentanil and food in squirrel monkeys.

Authors:  Samantha O Brown; Devin P Effinger; Rodrigo A Montoro; Nabil Daddaoua; Zuzana Justinova; Megan J Moerke; Charles W Schindler; Hank P Jedema; Charles W Bradberry
Journal:  Neuropsychopharmacology       Date:  2021-04-08       Impact factor: 8.294

9.  Psychosocial intervention and the reward system in pain and opioid misuse: new opportunities and directions.

Authors:  Eric L Garland
Journal:  Pain       Date:  2020-12       Impact factor: 7.926

10.  Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors.

Authors:  Qianwei Shen; Yulin Deng; Roberto Ciccocioppo; Nazzareno Cannella
Journal:  Front Psychiatry       Date:  2017-11-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.